ArticleACS omega2026
Enhanced Performance of IZO/ZnO Heterostructure Thin-Film Transistors and Its Biosensing Applications via Single-Precursor Solution Process.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report IZO/ZnO heterostructure thin film transistors (TFTs) fabricated by a single-precursor sol-gel process where a ZnO-rich surface region forms on an In-based oxide layer after annealing. The heterostructure improves the electrical response compared to a single-layer oxide TFT and provides a probe-free platform for biomolecule detection. As a demonstration, we detect pUC-18 plasmid DNA (2686 bp) over concentrations from 1 pg/mL to 10 ng/mL using transfer/output-curve changes as the sensing signal. The device exhibits a pronounced negative shift of threshold voltage and a strong increase in saturated current after exposure, enabling high sensitivity at low concentration; in particular, sensitivity exceeding 200% is obtained at 1 pg/mL, corresponding to a limit of detection of 1 pg/mL. These results suggest that the IZO/ZnO heterostructure TFT can serve as a simple and rapid probe-free biosensing platform produced via a low-cost solution process.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.